|
|
Vaccine Detail
|
gp100/IFA Vaccine |
| Vaccine Information |
- Vaccine Name: gp100/IFA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007489
- Type: peptide
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
- Description: To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials (Hailemichael et al., 2013).
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Primed T cells became dysfunctional and underwent antigen-driven, interferon-γ (IFN-γ)- and Fas ligand (FasL)-mediated apoptosis, resulting in hyporesponsiveness to subsequent vaccination. Provision of CD40-specific antibody, Toll-like receptor 7 (TLR7) agonist and interleukin-2 (IL-2) reduced T cell apoptosis but did not prevent vaccination-site sequestration. A nonpersisting vaccine formulation shifted T cell localization toward tumors, inducing superior antitumor activity while reducing systemic T cell dysfunction and promoting memory formation (Hailemichael et al., 2013).
|
| References |
Hailemichael et al., 2013: Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8⺠T cell sequestration, dysfunction and deletion. Nature medicine. 2013; 19(4); 465-472. [PubMed: 23455713].
|
|
